Keonte J Graves1, Arindam P Ghosh1, Norine Schmidt2, Peter Augostini3, W Evan Secor3, Jane R Schwebke1, David H Martin2,4, Patricia J Kissinger2, Christina A Muzny1. 1. Division of Infectious Diseases, University of Alabama at Birmingham. 2. Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana. 3. Centers for Disease Control and Prevention, Division of Parasitic Diseases and Malaria, Atlanta, Georgia. 4. Section of Infectious Diseases, Louisiana State University Health Sciences Center, New Orleans.
Abstract
BACKGROUND: Trichomonas vaginalis virus (TVV) is a non-segmented, 4.5-5.5 kilo-base pair (kbp), double-stranded RNA virus infecting T. vaginalis. The objectives of this study were to examine the TVV prevalence in US Trichomonas vaginalis isolates and TVV's associations with patient demographics, clinical outcomes, and metronidazole resistance. METHODS: Archived T. vaginalis isolates from the enrollment visits of 355 women participating in a T. vaginalis treatment trial in Birmingham, Alabama, were thawed and grown in culture. Their total RNA was extracted using a Trizol reagent. Contaminating, single-stranded RNA was precipitated using 4.0 M Lithium Chloride and centrifugation. The samples were analyzed by gel electrophoresis to visualize a 4.5 kbp band representative of TVV. In vitro testing for metronidazole resistance was also performed on 25/47 isolates obtained from the women's test of cure visits. RESULTS: TVV was detected in 142/355 (40%) isolates at the enrollment visit. Women with TVV-positive (TVV+) isolates were significantly older (P = .01), more likely to smoke (P = .04), and less likely to report a history of gonorrhea (P = .04). There was no association between the presence of clinical symptoms or repeat T. vaginalis infections with TVV+ isolates (P = .14 and P = .44, respectively). Of 25 test of cure isolates tested for metronidazole resistance, 0/10 TVV+ isolates demonstrated resistance, while 2/15 TVV-negative isolates demonstrated mild to moderate resistance (P = .23). CONCLUSIONS: Of 355 T. vaginalis isolates tested for TVV, T. vaginalis isolates tested for TVV, the prevalence was 40%. However, there was no association of TVV+ isolates with clinical symptoms, repeat infections, or metronidazole resistance. These results suggest that TVV may be commensal to T. vaginalis.
BACKGROUND:Trichomonas vaginalis virus (TVV) is a non-segmented, 4.5-5.5 kilo-base pair (kbp), double-stranded RNA virus infecting T. vaginalis. The objectives of this study were to examine the TVV prevalence in US Trichomonas vaginalis isolates and TVV's associations with patient demographics, clinical outcomes, and metronidazole resistance. METHODS: Archived T. vaginalis isolates from the enrollment visits of 355 women participating in a T. vaginalis treatment trial in Birmingham, Alabama, were thawed and grown in culture. Their total RNA was extracted using a Trizol reagent. Contaminating, single-stranded RNA was precipitated using 4.0 M Lithium Chloride and centrifugation. The samples were analyzed by gel electrophoresis to visualize a 4.5 kbp band representative of TVV. In vitro testing for metronidazole resistance was also performed on 25/47 isolates obtained from the women's test of cure visits. RESULTS: TVV was detected in 142/355 (40%) isolates at the enrollment visit. Women with TVV-positive (TVV+) isolates were significantly older (P = .01), more likely to smoke (P = .04), and less likely to report a history of gonorrhea (P = .04). There was no association between the presence of clinical symptoms or repeat T. vaginalis infections with TVV+ isolates (P = .14 and P = .44, respectively). Of 25 test of cure isolates tested for metronidazole resistance, 0/10 TVV+ isolates demonstrated resistance, while 2/15 TVV-negative isolates demonstrated mild to moderate resistance (P = .23). CONCLUSIONS: Of 355 T. vaginalis isolates tested for TVV, T. vaginalis isolates tested for TVV, the prevalence was 40%. However, there was no association of TVV+ isolates with clinical symptoms, repeat infections, or metronidazole resistance. These results suggest that TVV may be commensal to T. vaginalis.
Authors: Barbara Van Der Pol; James A Williams; Stephanie N Taylor; Catherine L Cammarata; Charles A Rivers; Barbara A Body; Melinda Nye; Deanna Fuller; Jane R Schwebke; Mathilda Barnes; Charlotte A Gaydos Journal: J Clin Microbiol Date: 2014-01-03 Impact factor: 5.948
Authors: Patricia Kissinger; Christina A Muzny; Leandro A Mena; Rebecca A Lillis; Jane R Schwebke; Laura Beauchamps; Stephanie N Taylor; Norine Schmidt; Leann Myers; Peter Augostini; William E Secor; Martina Bradic; Jane M Carlton; David H Martin Journal: Lancet Infect Dis Date: 2018-10-05 Impact factor: 25.071
Authors: Kristin N Parent; Yuko Takagi; Giovanni Cardone; Norman H Olson; Maria Ericsson; May Yang; Yujin Lee; John M Asara; Raina N Fichorova; Timothy S Baker; Max L Nibert Journal: MBio Date: 2013-04-02 Impact factor: 7.867
Authors: Robert D Kirkcaldy; Peter Augostini; Lenore E Asbel; Kyle T Bernstein; Roxanne P Kerani; Christie J Mettenbrink; Preeti Pathela; Jane R Schwebke; W Evan Secor; Kimberly A Workowski; Darlene Davis; Jim Braxton; Hillard S Weinstock Journal: Emerg Infect Dis Date: 2012-06 Impact factor: 6.883
Authors: T M Nelson; J C Borgogna; R D Michalek; D W Roberts; J M Rath; E D Glover; J Ravel; M D Shardell; C J Yeoman; R M Brotman Journal: Sci Rep Date: 2018-01-16 Impact factor: 4.996
Authors: Petr Rada; Ivan Hrdý; Alois Zdrha; Ravi Kumar Narayanasamy; Tamara Smutná; Jana Horáčková; Karel Harant; Vladimír Beneš; Seow-Chin Ong; Chih-Yu Tsai; Hong-Wei Luo; Cheng-Hsun Chiu; Petrus Tang; Jan Tachezy Journal: Front Microbiol Date: 2022-05-04 Impact factor: 5.640
Authors: Paul Barrow; Jean Claude Dujardin; Nicolas Fasel; Alex D Greenwood; Klaus Osterrieder; George Lomonossoff; Pier Luigi Fiori; Robert Atterbury; Matteo Rossi; Marco Lalle Journal: Virol J Date: 2020-09-29 Impact factor: 4.099